SDT employs ultrasound-responsive agents (e.g., TiO2 nanoparticles, porphyrin derivatives) to spatially confine ROS generation, inducing direct tumor cytotoxicity while concurrently reprogramming the tumor immune landscape to enhance anti-PD-1/PD-L1 therapeutic responses. The gene discussed is CD274; the disease is neoplasm.